Akademik Veri Yönetim Sistemi
Ankara Universitesi Eczacilik Fakultesi Dergisi, cilt.49, sa.2, ss.539-561, 2025 (Scopus)
Objective: Calcium calcium channel blockers (CCBs) have been shown to reduce arterial constriction by blocking calcium entry and interacting with binding sites identified on voltage-gated calcium channels. These compounds reduce arterial pressure by reducing total peripheral resistance. They improve myocardial oxygenation by disloading the heart and increasing coronary blood flow. In this study, an exploration has been undertaken concerning the makeup, variations, and attributes of calcium channels. Furthermore, an examination has been conducted regarding the categorization of compounds that block calcium channels, encompassing their molecular structure, mechanism of aciton, structure-activity relationships, metabolic pathways, recognized therapeutic applications in cardiovascular conditions, and broader therapeutic implications. Result and Discussion: Hypertension represents a substantial strategy to reduce the burden of cardiovascular and renal diseases associated with hypertension. Rational, integrated, and synergistic combination therapies which are recommended as a first-line strategy aimed at achieving the blood pressure targets. Among the currently available classes of antihypertensive drugs for the clinical treatment of hypertension, both in monotherapy and combination therapy, it has been shown that drugs inhibiting the renin-angiotensin system and calcium channel blockers (CCBs) are effective and safe in lowering and reaching the target blood pressure levels. Due to extensive scientific evidence demonstrating their efficacy in mitigating cardiovascular and renal complications linked to hypertension, calcium channel blockers have gained widespread use as a preferred class of antihypertensive medications over the last two decades, primarily attributed to their favorable tolerability profile.